Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
CYP3A4 and leukemia are reported together in 2 articles.
Gene
CYP3A4
- HGNC
- HGNC:2637
49articles
49mentions
2variants with confirmed gene link
Most co-reported phenotypes (articles)
diabetes mellitus 4Crohn disease 3hepatocellular carcinoma 3stroke 3autism spectrum disorder 2breast cancer 2hepatitis B 2leukemia 2
Reported variants (articles · ClinVar status)
Phenotype
Leukemia
652articles
652mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Drug Interaction of Dasatinib with Thymoquinone: A Pharmacokinetic Study in Rats.
PMID 41049424 | PMCID PMC12492365 | DOI 10.7150/ijms.109707 · International journal of medical sciences · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CYP3A4 | “Its metabolism by CYP3A4 and transported by efflux pump P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) render it susceptible to drug, food, and herbal interactions.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Dasatinib (DAS), a multi-kinase inhibitor targeting Src and BCR-ABL families, is approved for Ph+ acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CML).” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BCRP1 | “Furthermore, TQ pretreatment inhibited CYP3A4 and Pgp and BCRP1 in the liver and lumen tissues.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Its metabolism by CYP3A4 and transported by efflux pump P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) render it susceptible to drug, food, and herbal interactions.” | 0.98 | phenotype_alias_lexicon_v2 |
CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.
PMID 40613206 | DOI 10.31083/FBS36269 · Frontiers in bioscience (Scholar edition) · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CYP3A4 | “CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CYP3A5 | “CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.” | 0.98 | hgnc_dict_v1 |